Agenus Q4 2022 Earnings Report
Key Takeaways
Agenus reported revenue of $28 million and a net loss of $74 million for the fourth quarter of 2022. The company ended the year with a cash, cash equivalent, and short-term investment balance of $193 million.
Agenus entered 2023 with strong momentum across its clinical pipeline of immuno-oncology programs.
Botensilimab and balstilimab show exciting potential in combination to treat a broad spectrum of treatment-resistant cancers.
Botensilimab's clinical activity in advanced and refractory cancers has generated considerable interest from experts worldwide.
Agenus is expediting the expansion of its botensilimab/balstilimab development program in MSS CRC and other priority indications.
Agenus
Agenus
Forward Guidance
Agenus is focused on advancing its clinical pipeline and strategic partnerships in 2023.